|Application ||WB, IHC-P, FC, E|
|Calculated MW||68997 Da|
|Antigen Region||579-607 aa|
|Other Names||Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial, 70 kDa mitochondrial autoantigen of primary biliary cirrhosis, PBC, Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex, M2 antigen complex 70 kDa subunit, Pyruvate dehydrogenase complex component E2, PDC-E2, PDCE2, DLAT, DLTA|
|Target/Specificity||This DLAT antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 579-607 amino acids from the C-terminal region of human DLAT.|
|Precautions||DLAT Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links the glycolytic pathway to the tricarboxylic cycle.|
|Cellular Location||Mitochondrion matrix.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
DLAT encodes component E2 of the multi-enzyme pyruvate dehydrogenase complex (PDC). PDC resides in the inner mitochondrial membrane and catalyzes the conversion of pyruvate to acetyl coenzyme A. The protein product of this gene, dihydrolipoamide acetyltransferase, accepts acetyl groups formed by the oxidative decarboxylation of pyruvate and transfers them to coenzyme A. Dihydrolipoamide acetyltransferase is the antigen for antimitochondrial antibodies. These autoantibodies are present in nearly 95% of patients with the autoimmune liver disease primary biliary cirrhosis (PBC). In PBC, activated T lymphocytes attack and destroy epithelial cells in the bile duct where this protein is abnormally distributed and overexpressed. PBC enventually leads to cirrhosis and liver failure.
Trynka, G., et al. Gut 58(8):1078-1083(2009)
Lleo, A., et al. Hepatology 49(3):871-879(2009)
Korotchkina, L.G., et al. FEBS Lett. 582(3):468-472(2008)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.